Skip to content

Prolotherapy in MPDS Patients

Comparison of the Efficacy of Prolotherapy (Dextrose 15 percent) and Local Anesthetic Injection in Myofascial Pain Dysfunction Syndrome (MPDS) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087911
Enrollment
60
Registered
2025-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K089- Disorder of teeth and supporting structures, unspecified

Interventions

Intervention1: (Dextrose 15%) and Local Anesthetic Injection: 0.3-0.4 ml of the solution will be given as trigger point injection at each pain site . Control Intervention1: Local anesthetic injection

Sponsors

Ajay kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age Eligible for study : 18 Years to 65 Patients diagnosed with Myofascial pain dysfunction Syndrome (MPDS) according to LASKINs criteria. At least one active Myofascial trigger point in the masseter muscle. Patients with symptoms more than 1 month. Cases who did not get relieved from any physical therapy or medications.

Exclusion criteria

Exclusion criteria: Having a sensory defect in the area to be injected. Active inflammatory, rheumatic, or infectious disease. Those who use anticoagulants & those with bleeding disorders. Patients whose skin surface is not intact in the area to be injected. Those who are allergic to local anesthetic drug or dextrose. Those who have had a trigger point injection in the last 6 months. Those who are pregnant. Those who have undergone shoulder surgery in the last 1 year.

Design outcomes

Primary

MeasureTime frame
Pressure pain intensity PPI scores will be determined on a 4-point scale: 0 no reporting of pain and no visible reaction; 1 reporting of pain; 2 painful tenderness and visible reaction on the face; 3 severe pain and marked visible reaction or avoidance. Pain intensity VAS Scale 0 to 10 Timepoint: at baseline, after 3 weeks, after 6 weeks and after 12 weeks.

Secondary

MeasureTime frame
Mouth opening Will be assessed by measuring inter-incisal distance in millimeters All these parameters will be assessed at baseline, 1st week, 2nd week 3rd week & 4th week after commencement of treatment. After 1 month of active therapy, the patient will be followed up monthly for period of 2 months to check for any recurrences. Timepoint: at baseline, after 1 week, 2 week , 3 week & 4 week

Countries

India

Contacts

Public ContactDr Ajay kumar

Faculty of dental sciences, ims, bhu

adit@bhu.ac.in9451525522

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026